GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006979111 | Esophagus | ESCC | response to oxidative stress | 303/8552 | 446/18723 | 7.15e-22 | 1.30e-19 | 303 |
GO:0062197111 | Esophagus | ESCC | cellular response to chemical stress | 234/8552 | 337/18723 | 5.37e-19 | 5.97e-17 | 234 |
GO:0034599111 | Esophagus | ESCC | cellular response to oxidative stress | 197/8552 | 288/18723 | 3.76e-15 | 2.15e-13 | 197 |
GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
GO:004312318 | Esophagus | ESCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 132/8552 | 186/18723 | 2.07e-12 | 8.58e-11 | 132 |
GO:0043122110 | Esophagus | ESCC | regulation of I-kappaB kinase/NF-kappaB signaling | 167/8552 | 249/18723 | 6.11e-12 | 2.32e-10 | 167 |
GO:000724919 | Esophagus | ESCC | I-kappaB kinase/NF-kappaB signaling | 183/8552 | 281/18723 | 3.02e-11 | 1.01e-09 | 183 |
GO:0000302111 | Esophagus | ESCC | response to reactive oxygen species | 150/8552 | 222/18723 | 3.06e-11 | 1.02e-09 | 150 |
GO:003461420 | Esophagus | ESCC | cellular response to reactive oxygen species | 103/8552 | 155/18723 | 1.34e-07 | 2.17e-06 | 103 |
GO:000726510 | Esophagus | ESCC | Ras protein signal transduction | 201/8552 | 337/18723 | 1.44e-07 | 2.30e-06 | 201 |
GO:00510908 | Esophagus | ESCC | regulation of DNA-binding transcription factor activity | 252/8552 | 440/18723 | 5.22e-07 | 6.97e-06 | 252 |
GO:00182099 | Esophagus | ESCC | peptidyl-serine modification | 196/8552 | 338/18723 | 3.07e-06 | 3.47e-05 | 196 |
GO:001810515 | Esophagus | ESCC | peptidyl-serine phosphorylation | 184/8552 | 315/18723 | 3.22e-06 | 3.61e-05 | 184 |
GO:00510918 | Esophagus | ESCC | positive regulation of DNA-binding transcription factor activity | 155/8552 | 260/18723 | 3.83e-06 | 4.14e-05 | 155 |
GO:0043434111 | Esophagus | ESCC | response to peptide hormone | 234/8552 | 414/18723 | 4.93e-06 | 5.21e-05 | 234 |
GO:003320914 | Esophagus | ESCC | tumor necrosis factor-mediated signaling pathway | 67/8552 | 99/18723 | 7.87e-06 | 7.72e-05 | 67 |
GO:003461220 | Esophagus | ESCC | response to tumor necrosis factor | 149/8552 | 253/18723 | 1.47e-05 | 1.33e-04 | 149 |
GO:003248112 | Esophagus | ESCC | positive regulation of type I interferon production | 42/8552 | 58/18723 | 3.27e-05 | 2.70e-04 | 42 |
GO:000941020 | Esophagus | ESCC | response to xenobiotic stimulus | 253/8552 | 462/18723 | 4.55e-05 | 3.58e-04 | 253 |
GO:001003827 | Esophagus | ESCC | response to metal ion | 208/8552 | 373/18723 | 5.02e-05 | 3.90e-04 | 208 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05417310 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa0522216 | Esophagus | ESCC | Small cell lung cancer | 69/4205 | 92/8465 | 5.40e-07 | 3.85e-06 | 1.97e-06 | 69 |
hsa0516338 | Esophagus | ESCC | Human cytomegalovirus infection | 148/4205 | 225/8465 | 5.73e-07 | 4.00e-06 | 2.05e-06 | 148 |
hsa0521517 | Esophagus | ESCC | Prostate cancer | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
hsa0516016 | Esophagus | ESCC | Hepatitis C | 107/4205 | 157/8465 | 1.75e-06 | 1.08e-05 | 5.55e-06 | 107 |
hsa0516114 | Esophagus | ESCC | Hepatitis B | 108/4205 | 162/8465 | 7.68e-06 | 4.15e-05 | 2.12e-05 | 108 |
hsa0406814 | Esophagus | ESCC | FoxO signaling pathway | 89/4205 | 131/8465 | 1.56e-05 | 7.98e-05 | 4.09e-05 | 89 |
hsa0462513 | Esophagus | ESCC | C-type lectin receptor signaling pathway | 73/4205 | 104/8465 | 1.57e-05 | 7.98e-05 | 4.09e-05 | 73 |
hsa0512019 | Esophagus | ESCC | Epithelial cell signaling in Helicobacter pylori infection | 52/4205 | 70/8465 | 2.17e-05 | 1.07e-04 | 5.47e-05 | 52 |
hsa0465734 | Esophagus | ESCC | IL-17 signaling pathway | 66/4205 | 94/8465 | 3.93e-05 | 1.75e-04 | 8.99e-05 | 66 |
hsa05145111 | Esophagus | ESCC | Toxoplasmosis | 76/4205 | 112/8465 | 6.83e-05 | 2.90e-04 | 1.48e-04 | 76 |
hsa0522113 | Esophagus | ESCC | Acute myeloid leukemia | 49/4205 | 67/8465 | 7.43e-05 | 3.07e-04 | 1.57e-04 | 49 |
hsa0516213 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
hsa0462132 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
hsa0415013 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
hsa0406412 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
hsa0523511 | Esophagus | ESCC | PD-L1 expression and PD-1 checkpoint pathway in cancer | 58/4205 | 89/8465 | 2.19e-03 | 6.16e-03 | 3.16e-03 | 58 |
hsa0514213 | Esophagus | ESCC | Chagas disease | 65/4205 | 102/8465 | 2.81e-03 | 7.59e-03 | 3.89e-03 | 65 |
hsa0465914 | Esophagus | ESCC | Th17 cell differentiation | 68/4205 | 108/8465 | 3.53e-03 | 9.30e-03 | 4.76e-03 | 68 |
hsa0462311 | Esophagus | ESCC | Cytosolic DNA-sensing pathway | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CHUK | SNV | Missense_Mutation | rs184250593 | c.1654N>T | p.Arg552Cys | p.R552C | O15111 | protein_coding | deleterious(0) | probably_damaging(0.925) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CHUK | SNV | Missense_Mutation | novel | c.1513N>A | p.Glu505Lys | p.E505K | O15111 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CHUK | SNV | Missense_Mutation | rs747387872 | c.757N>T | p.Arg253Trp | p.R253W | O15111 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CHUK | SNV | Missense_Mutation | novel | c.590N>T | p.Pro197Leu | p.P197L | O15111 | protein_coding | tolerated(0.08) | possibly_damaging(0.836) | TCGA-AR-A24R-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
CHUK | SNV | Missense_Mutation | novel | c.241G>A | p.Glu81Lys | p.E81K | O15111 | protein_coding | deleterious(0.05) | benign(0.138) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CHUK | SNV | Missense_Mutation | novel | c.195G>A | p.Met65Ile | p.M65I | O15111 | protein_coding | tolerated(0.07) | benign(0.266) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
CHUK | SNV | Missense_Mutation | | c.1183N>A | p.Glu395Lys | p.E395K | O15111 | protein_coding | tolerated(0.09) | benign(0.037) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
CHUK | deletion | Frame_Shift_Del | novel | c.2167_2168delNN | p.Ile723TyrfsTer3 | p.I723Yfs*3 | O15111 | protein_coding | | | TCGA-AC-A3OD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CHUK | SNV | Missense_Mutation | | c.751G>A | p.Glu251Lys | p.E251K | O15111 | protein_coding | tolerated(0.08) | probably_damaging(0.936) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CHUK | SNV | Missense_Mutation | | c.1395G>C | p.Met465Ile | p.M465I | O15111 | protein_coding | deleterious(0.03) | benign(0.119) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1147 | CHUK | SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME, KINASE, TRANSCRIPTION FACTOR | | N-(3-OXODODECANOYL)HOMOSERINELACTONE | CHEMBL8483 | 18566250 |
1147 | CHUK | SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME, KINASE, TRANSCRIPTION FACTOR | | LAUROGUADINE | LAUROGUADINE | |
1147 | CHUK | SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME, KINASE, TRANSCRIPTION FACTOR | inhibitor | 328083500 | CHEMBL592893 | |
1147 | CHUK | SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME, KINASE, TRANSCRIPTION FACTOR | | 6R-SENECIONYLCHAPARRIN | CHEMBL564009 | 19199792 |
1147 | CHUK | SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME, KINASE, TRANSCRIPTION FACTOR | inhibitor | 340590276 | | |
1147 | CHUK | SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME, KINASE, TRANSCRIPTION FACTOR | inhibitor | 348353652 | | |
1147 | CHUK | SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME, KINASE, TRANSCRIPTION FACTOR | | GLAUCARUBINONE | GLAUCARUBINONE | 19199792 |
1147 | CHUK | SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME, KINASE, TRANSCRIPTION FACTOR | | PEPEROMIN E | PEPEROMIN E | 19559609 |
1147 | CHUK | SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME, KINASE, TRANSCRIPTION FACTOR | | VITAMIN C | | 11120850 |
1147 | CHUK | SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME, KINASE, TRANSCRIPTION FACTOR | allosteric modulator | 178102297 | BMS-345541 | |